Last reviewed · How we verify
PSMA-positive metastatic castration-resistant prostate cancer
Approved treatments
- Pluvicto · Aaa Usa Novartis
Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells. - Pluvicto · VA Office of Research and Development
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- PSMA-positive metastatic castration-resistant prostate cancer patent landscape — cliff calendar, originator estates, attackable patents
- PSMA-positive metastatic castration-resistant prostate cancer treatment landscape brief
- PSMA-positive metastatic castration-resistant prostate cancer treatment updates RSS
Frequently asked questions about PSMA-positive metastatic castration-resistant prostate cancer
What drugs treat PSMA-positive metastatic castration-resistant prostate cancer?
Tracked treatments include Pluvicto.
What is the treatment for PSMA-positive metastatic castration-resistant prostate cancer?
Standard treatment for PSMA-positive metastatic castration-resistant prostate cancer includes Pluvicto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: PSMA-positive metastatic castration-resistant prostate cancer patent cliff · PSMA-positive metastatic castration-resistant prostate cancer CI report
- Treatment: Pluvicto · Aaa Usa Novartis
- Treatment: Pluvicto · VA Office of Research and Development
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing